Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis

Future Microbiology

Volumn 8, Issue 7, 2013, Pages 855-875

  Jackson, Mary ^a   McNeil, Michael R ^a   Brennan, Patrick J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

antibiotic; arabinogalactan; cell envelope; Mycobacterium; mycolic acids; peptidoglycan; tuberculosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ARABINOGALACTAN; BCG VACCINE; BDM31343; BEDAQUILINE; BENZIMIDAZOLE; BTZ 043; BTZ043; CARBAPENEM; CLAVULANIC ACID; CYCLOSERINE; DECAPRENYL PHOSPHATE; ETHAMBUTOL; FOSMIDOMYCIN; ISONIAZID; MEROPENEM; MYCOLIC ACID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PENICILLIN DERIVATIVE; PEPTIDOGLYCAN; PYRAZINAMIDE; PYRAZINOIC ACID; PYRIMIDINE; RIFAMPICIN; THIOACETAZONE; THIOLACTOMYCIN; THIOUREA DERIVATIVE; TRICLOSAN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL MEMBRANE; BIOGENESIS; BIOSYNTHESIS; CELL METABOLISM; CELL WALL; DRUG DEVELOPMENT; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALARIA FALCIPARUM; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTER MEMBRANE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; REPORTER GENE; REVIEW; STREPTOMYCES LAVENDULAE;

ANIMALS; ANTITUBERCULAR AGENTS; CELL WALL; DRUG EVALUATION, PRECLINICAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84880130708     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.52     Document Type: Review

References (114)

1. Center for Disease Control and Prevention: emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000-2004. MMWR Morb. Mortal. Wkly Rep. 55(11), 301-305 (2006).
2. Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. Int. J. Tuberc. Lung Dis. 16(6), 724-732 (2012).
3. Bhamidi S, Shi L, Chatterjee D, Belisle JT, Crick DC, McNeil MR. A bioanalytical method to determine the cell wall composition of Mycobacterium tuberculosis grown in vivo. Anal. Biochem. 421(1), 240-249 (2012).
4. Ryan GJ, Hoff DR, Driver ER et al. Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach. PLoS One 5(6), e11108 (2010).
5. Cunningham AF, Spreadbury CL. Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton ?-crystallin homolog. J. Bacteriol. 180(4), 801-808 (1998).
6. De Chastellier C, Thilo L. Phagosome maturation and fusion with lysosomes in relation to surface property and size of the phagocytic particle. Eur. J. Cell Biol. 74(1), 49-62 (1997).
7. Glickman MS, Cox JS, Jacobs WR Jr. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol. Cell 5, 717-727 (2000).
8. Gupta R, Lavollay M, Mainardi JL, Arthur M, Bishai WR, Lamichhane G. The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat. Med. 16(4), 466-469 (2010).
9. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323(5918), 1215-1218 (2009).
10. Lechartier B, Hartkoorn RC, Cole ST. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56(11), 5790-5793 (2012).
11. Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob. Agents Chemother. 54(7), 2840-2846 (2010).
12. Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J. Antimicrob. Chemother. 58(2), 332-337 (2006).
13. Vilcheze C, Baughn AD, Tufariello J et al. Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrob. Agents Chemother. 55(8), 3889-3898 (2011).
14. Reddy VM, Einck L, Nacy CA. In vitro antimycobacterial activities of capuramycin analogues. Antimicrob. Agents Chemother. 52(2), 719-721 (2008).
15. Winder FG. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of mycobacteria. In: The Biology of the Mycobacteria. Ratledge C, Stanford J (Eds). Academic Press, London, UK, 353-438 (1982).
16. Vilcheze C, Jacobs WR Jr. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu. Rev. Microbiol. 61, 35-50 (2007).
17. Davidson LA, Takayama K. Isoniazid inhibition of the synthesis of monounsaturated long-chain fatty acids in Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 16, 104-105 (1979).
18. Banerjee A, Dubnau E, Quémard A et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227-230 (1994).
19. Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr, Sacchettini JC. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279(5347), 98-102 (1998).
20. Winder FG, Collins PB, Whelan D. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. J. Gen. Microbiol. 66, 379-380 (1971).
21. Nishida CR, Ortiz De Montellano PR. Bioactivation of antituberculosis thioamide and thiourea prodrugs by bacterial and mammalian flavin monooxygenases. Chem. Biol. Interact. 192(1-2), 21-25 (2011).
22. Hartkoorn RC, Sala C, Neres J et al. Towards a new tuberculosis drug: pyridomycin-nature's isoniazid. EMBO Mol. Med. 4(10), 1032-1042 (2012).
23. Kremer L, Douglas JD, Baulard AR et al. Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J. Biol. Chem. 275(22), 16857-16864 (2000).
24. Grzegorzewicz AE, Korduláková J, Jones V et al. A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. J. Biol. Chem. 287(46), 38434-38441 (2012).
25. Mikušová K, Slayden RA, Besra GS, Brennan PJ. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob. Agents Chemother. 39(11), 2484-2489 (1995).
26. Belanger AE, Besra GS, Ford ME et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Natl Acad. Sci. USA 93, 11919-11924 (1996).
27. Shi W, Zhang X, Jiang X et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333(6049), 1630-1632 (2011).
28. Zimhony O, Cox JS, Welch JT, Vilchèze C, Jacobs WR Jr. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. 6(8), 1043-1047 (2000).
29. Kaur D, Guerin ME, Skovierova H, Brennan PJ, Jackson M. Chapter 2: biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis. Adv. Appl. Microbiol. 69, 23-78 (2009).
30. Sala C, Hartkoorn RC. Tuberculosis drugs: new candidates and how to find more. Future Microbiol. 6(6), 617-633 (2011).
31. Coxon GD, Cooper CB, Gillespie SH, McHugh TD. Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery. J. Infect. Dis. 205(Suppl. 2), S258-S264 (2012).
32. Scott DE, Coyne AG, Hudson SA, Abell C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 51(25), 4990-5003 (2012).
33. Barry CE, Crick DC, McNeil MR. Targeting the formation of the cell wall core of Mycobacterium tuberculosis. Infect. Dis. Drug Targets 7(2), 182-202 (2007).
34. Sivendran S, Jones V, Sun D et al. Identification of triazinoindol- benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-d-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC). Bioorg. Med. Chem. 18(2), 896-908 (2010).
35. Zhang W, Jones VC, Scherman MS et al. Expression, essentiality, and a microtiter plate assay for mycobacterial GlmU, the bifunctional glucosamine-1-phosphate acetyltransferase and N-acetylglucosamine-1-phosphate uridyltransferase. Int. J. Biochem. Cell Biol. 40(11), 2560-2571 (2008).
36. Singla D, Anurag M, Dash D, Raghava GP. A web server for predicting inhibitors against bacterial target GlmU protein. BMC Pharmacol. 11, 5 (2011).
37. Tangallapally RP, Yendapally R, Lee RE et al. Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents. J. Med. Chem. 47(21), 5276-5283 (2004).
38. Hurdle JG, Lee RB, Budha NR et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J. Antimicrob. Chemother. 62(5), 1037-1045 (2008).
39. Rakesh, Bruhn D, Madhura DB et al. Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. Bioorg. Med. Chem. 20(20), 6063-6072 (2012).
40. Wang Y, Hess TN, Jones V, Zhou JZ, McNeil MR, Andrew McCammon J. Novel inhibitors of Mycobacterium tuberculosis dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD) identified by virtual screening. Bioorg. Med. Chem. Lett. 21(23), 7064-7067 (2011).
41. Leger M, Gavalda S, Guillet V et al. The dual function of the Mycobacterium tuberculosis FadD32 required for mycolic acid biosynthesis. Chem. Biol. 16(5), 510-519 (2009).
42. Bergeret F, Gavalda S, Chalut C et al. Biochemical and structural study of the atypical acyltransferase domain from the mycobacterial polyketide synthase Pks13. J. Biol. Chem. 287(40), 33675-33690 (2012).
43. Carroll P, Faray-Kele MC, Parish T. Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach. Appl. Environ. Microbiol. 77(14), 5040-5043 (2011).
44. Galandrin S, Guillet V, Rane RS et al. Assay development for identifying inhibitors of the mycobacterial FadD32 activity. J. Biomol. Screen. 18(5), 576-587 (2013).
45. Favrot L, Ronning DR. Targeting the mycobacterial envelope for tuberculosis drug development. Expert Rev. Anti. Infect. Ther. 10(9), 1023-1036 (2012).
46. Warrier T, Tropis M, Werngren J et al. Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis. Antimicrob. Agents Chemother. 56(4), 1735-1743 (2012).
47. Bruning JB, Murillo AC, Chacon O, Barletta RG, Sacchettini JC. Structure of the Mycobacterium tuberculosis d-alanine:d-alanine ligase, a target of the antituberculosis drug d-cycloserine. Antimicrob. Agents Chemother. 55(1), 291-301 (2011).
48. Guzman JD, Wube A, Evangelopoulos D et al. Interaction of N-methyl-2-alkenyl-4-quinolones with ATP-dependent MurE ligase of Mycobacterium tuberculosis: antibacterial activity, molecular docking and inhibition kinetics. J. Antimicrob. Chemother. 66(8), 1766-1772 (2011).
49. Molle V, Kremer L. Division and cell envelope regulation by Ser/Thr phosphorylation: Mycobacterium shows the way. Mol. Microbiol. 75(5), 1064-1077 (2010).
50. Magnet S, Hartkoorn RC, Szekely R et al. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinb.) 90(6), 354-360 (2010).
51. Danilenko VN, Osolodkin DI, Lakatosh SA, Preobrazhenskaya MN, Shtil AA. Bacterial eukaryotic type serine-threonine protein kinases: from structural biology to targeted anti-infective drug design. Curr. Top. Med. Chem. 11(11), 1352-1369 (2011).
52. Lougheed KE, Osborne SA, Saxty B et al. Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents. Tuberculosis (Edinb.) 91(4), 277-286 (2011).
53. Chapman TM, Bouloc N, Buxton RS et al. Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. 22(9), 3349-3353 (2012).
54. Gonzalo Asensio J, Maia C, Ferrer NL et al. The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis. J. Biol. Chem. 281(3), 1313-1316 (2006).
55. Walters SB, Dubnau E, Kolesnikova I, Laval F, Daffé M, Smith I. The Mycobacterium tuberculosis PhoPR two-component system regulates genes essential for virulence and complex lipid biosynthesis. Mol. Microbiol. 60(2), 312-330 (2006).
56. Frigui W, Bottai D, Majlessi L et al. Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. PLoS Pathog. 4(2), e33 (2008).
57. Gonzalo-Asensio J, Mostowy S, Harders-Westerveen J et al. PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PLoS ONE 3(10), e3496 (2008).
58. Lee JS, Krause R, Schreiber J et al. Mutation in the transcriptional regulator PhoP contributes to avirulence of Mycobacterium tuberculosis H37Ra strain. Cell Host Microbe 3(2), 97-103 (2008).
59. Ryndak M, Wang S, Smith I. PhoP, a key player in Mycobacterium tuberculosis virulence. Trends Microbiol. 16(11), 528-534 (2008).
60. Chesne-Seck ML, Barilone N, Boudou F et al. A point mutation in the two-component regulator PhoP-PhoR accounts for the absence of polyketide-derived acyltrehaloses but not that of phthiocerol dimycocerosates in Mycobacterium tuberculosis H37Ra. J. Bacteriol. 190(4), 1329-1334 (2008).
61. Camacho LR, Constant P, Raynaud C et al. Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier. J. Biol. Chem. 276(23), 19845-19854 (2001).
62. Sambou T, Dinadayala P, Stadthagen G et al. Capsular glucan and intracellular glycogen of Mycobacterium tuberculosis: biosynthesis and impact on the persistence in mice. Mol. Microbiol. 70(3), 762-774 (2008).
63. Kalscheuer R, Syson K, Veeraraghavan U et al. Self-poisoning of Mycobacterium tuberculosis by targeting GlgE in an ?-glucan pathway. Nat. Chem. Biol. 6(5), 376-384 (2010).
64. Feltcher ME, Sullivan JT, Braunstein M. Protein export systems of Mycobacterium tuberculosis: novel targets for drug development? Future Microbiol. 5(10), 1581-1597 (2010).
65. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6(1), 29-40 (2007).
66. Wei JR, Krishnamoorthy V, Murphy K et al. Depletion of antibiotic targets has widely varying effects on growth. Proc. Natl Acad. Sci. USA 108(10), 4176-4181 (2011).
67. Kim JH, Wei JR, Wallach JB, Robbins RS, Rubin EJ, Schnappinger D. Protein inactivation in mycobacteria by controlled proteolysis and its application to deplete the ? subunit of RNA polymerase. Nucleic Acids Res. 39(6), 2210-2220 (2011).
68. Park SW, Klotzsche M, Wilson DJ et al. Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog. 7(9), e1002264 (2011).
69. Alland D, Steyn AJ, Weisbrod T, Aldrich K, Jacobs WR Jr. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J. Bacteriol. 182(7), 1802-1811 (2000).
70. Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE 3rd. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 5(2), 172-187 (2003).
71. Barry CE 3rd, Blanchard JS. The chemical biology of new drugs in the development for tuberculosis. Curr. Opin. Chem. Biol. 14(4), 456-466 (2010).
72. Tahlan K, Wilson R, Kastrinsky DB et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56(4), 1797-1809 (2012).
73. Koga T, Fukuoka T, Doi N et al. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. J. Antimicrob. Chemother. 54(4), 755-760 (2004)
74. Nikonenko BV, Reddy VM, Protopopova M, Bogatcheva E, Einck L, Nacy CA. Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis. Antimicrob. Agents Chemother. 53(7), 3138-3139 (2009).
75. Kaprelyants AS, Mukamolova GV, Ruggiero A et al. Resuscitation-promoting factors (Rpf): in search of inhibitors. Protein Pept. Lett. 19(10), 1026-1034 (2012).
76. England K, Boshoff HI, Arora K et al. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 56(6), 3384-3387 (2012).
77. Kumar P, Arora K, Lloyd JR et al. Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol. Microbiol. 86(2), 367-381 (2012).
78. Lavollay M, Arthur M, Fourgeaud M et al. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation. J. Bacteriol. 190(12), 4360-4366 (2008).
79. Erdemli SB, Gupta R, Bishai WR, Lamichhane G, Amzel LM, Bianchet MA. Targeting the cell wall of Mycobacterium tuberculosis: structure and mechanism of L,D-transpeptidase 2. Structure 20(12), 2103-2115 (2012).
80. Freundlich JS, Wang F, Vilcheze C et al. Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. Chem. Med. Chem. 4(2), 241-248 (2009).
81. Menendez C, Gau S, Lherbet C et al. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents. Eur. J. Med. Chem. 46(11), 5524-5531 (2011).
82. Boechat N, Ferreira VF, Ferreira SB et al. Novel 1,2,3-triazole derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain. J. Med. Chem. 54(17), 5988-5999 (2011).
83. Pan P, Tonge PJ. Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. Curr. Top. Med. Chem. 12(7), 672-693 (2012).
84. Bhowruth V, Brown AK, Reynolds RC et al. Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. 16, 4743-4747 (2006).
85. Liav A, Angala SK, Brennan PJ. N-glycosyl-N'-(p-isoamyloxy)phenyl)- thiourea derivatives: potential anti-TB therapeutic agents. Synt. Commun. 38, 1176-1183 (2008).
86. Liav A, Angala SK, Brennan PJ, Jackson M. N-D-Aldopentofuranosyl-N'-[p- (isoamyloxy) phenyl]-thiourea derivatives: potential anti-TB therapeutic agents. Bioorg. Med. Chem. Lett. 18, 2649-2651 (2008).
87. Coxon GD, Craig D, Corrales RM, Vialla E, Gannoun-Zaki L, Kremer L. Synthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues. PLoS ONE 8(1), e53162 (2013).
88. Kapilashrami K, Bommineni GR, Machutta CA et al. Thiolactomycin-based ?-ketoacyl-AcpM synthase A (KasA) inhibitors: fragment-based inhibitor discovery using transient one-dimensional nuclear overhauser effect NMR spectroscopy. J. Biol. Chem. 288(9), 6045-6052 (2013).
89. Obiol-Pardo C, Rubio-Martinez J, Imperial S. The methylerythritol phosphate (MEP) pathway for isoprenoid biosynthesis as a target for the development of new drugs against tuberculosis. Curr. Med. Chem. 18(9), 1325-1338 (2011).
90. Uh E, Jackson ER, San Jose G et al. Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. Bioorg. Med. Chem. Lett. 21(23), 6973-6976 (2011).
91. Bogatcheva E, Hanrahan C, Nikonenko B et al. Identification of SQ609 as a lead compound from a library of dipiperidines. Bioorg. Med. Chem. Lett. 21(18), 5353-5357 (2011).
92. Weber W, Schoenmakers R, Keller B et al. A synthetic mammalian gene circuit reveals antituberculosis compounds. Proc. Natl Acad. Sci. USA 105(29), 9994-9998 (2008).
93. Willand N, Dirie B, Carette X et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat. Med. 15(5), 537-544 (2009).
94. Grau T, Selchow P, Tigges M et al. Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56(2), 1142-1145 (2012).
95. Villemagne B, Crauste C, Flipo M, Baulard AR, Deprez B, Willand N. Tuberculosis: the drug development pipeline at a glance. Eur. J. Med. Chem. 51, 1-16 (2012).
96. Pethe K, Sequeira PC, Agarwalla S et al. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat. Commun. 1, 57 (2010).
97. Makarov V, Manina G, Mikusova K et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324(5928), 801-804 (2009).
98. Trefzer C, Skovierova H, Buroni S et al. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-?-d-ribofuranose 2'-oxidase DprE1. J. Am. Chem. Soc. 134(2), 912-915 (2012
99. Trefzer C, Rengifo-Gonzalez M, Hinner MJ et al. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-?-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. J. Am. Chem. Soc. 132(39), 13663-13665 (2010).
100. Neres J, Pojer F, Molteni E et al. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci. Transl. Med. 4(150), 150ra121 (2012).
101. Batt SM, Jabeen T, Bhowruth V et al. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl Acad. Sci. USA 109(28), 11354-11359 (2012).
102. Christophe T, Jackson M, Jeon HK et al. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5(10), e1000645 (2009).
103. Stanley SA, Grant SS, Kawate T et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7(8), 1377-1384 (2012).
104. Grzegorzewicz AE, Pham H, Gundi VA et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 8(4), 334-341 (2012).
105. La Rosa V, Poce G, Canseco JO et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 56(1), 324-331 (2012).
106. Brown JR, North EJ, Hurdle JG et al. The structure-activity relationship of urea derivatives as anti-tuberculosis agents. Bioorg. Med. Chem. 19(18), 5585-5595 (2011).
107. Scherman MS, North EJ, Jones V et al. Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability. Bioorg. Med. Chem. 20(10), 3255-3262 (2012).
108. Andries K, Verhasselt P, Guillemont J et al. A diaryquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227 (2005).
109. Zhang Y, Yew WW, Barer MR. Targeting persisters for tuberculosis control. Antimicrob. Agents Chemother. 56(5), 2223-2230 (2012).
110. Duckworth BP, Geders TW, Tiwari D et al. Bisubstrate adenylation inhibitors of biotin protein ligase from Mycobacterium tuberculosis. Chem. Biol. 18(11), 1432-1441 (2011).
111. Zhang M, Sala C, Hartkoorn RC, Dhar N, Mendoza-Losana A, Cole ST. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob. Agents Chemother. 56(11), 5782-5789 (2012).
112. Hoffmann C, Leis A, Niederweis M, Plitzko JM, Engelhardt H. Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc. Natl Acad. Sci. USA 105(10), 3963-3967 (2008).
113. Sani M, Houben ENG, Geurtsen J et al. Direct visualization by cryo-EM of the mycobacterial capsular layer: a labile structure containing ESX-1-secreted proteins. PLoS Pathog. 6(3), e1000794 (2010).
114. Zuber B, Chami M, Houssin C, Dubochet J, Griffiths G, Daffé M. Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. J. Bacteriol. 190(16), 5672-5680 (2008). Allergy and Infectious Diseases Allergy and Infectious Diseases Allergy and Infectious Diseases